NASDAQ : HCWB
HCW Biologics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.46M |
| Enterprise Value | 8.28M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.24M |
| Shares Outstanding | 2.24M |
| Shares Change (YoY) | +285.74% |
| Shares Change (QoQ) | +46.85% |
| Owned by Insiders (%) | 8.34% |
| Owned by Institutions (%) | 5.11% |
| Float | 2.05M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.06 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.26 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -151.36% |
| Return on Assets (ROA) | -13.88% |
| Return on Invested Capital (ROIC) | -37.30% |
| Return on Capital Employed (ROCE) | -76.16% |
| Weighted Average Cost of Capital (WACC) | 9.38% |
| Revenue Per Employee | $192,034 |
| Profits Per Employee | -$611,719 |
| Employee Count | 35 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 330,186 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -95.24% |
| 50-Day Moving Average | 1.92 |
| 200-Day Moving Average | 4.12 |
| Relative Strength Index (RSI) | 31.31 |
| Average Volume (20 Days) | 158,442 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 37,709 |
| Short Previous Month | 60,941 |
| Short % of Shares Out | 1.69% |
| Short % of Float | 1.84% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.72M |
| Gross Profit | 6.45M |
| Operating Income | -6.18M |
| Pretax Income | -5.25M |
| Net Income | -21.41M |
| EBITDA | -5.58M |
| EBIT | -6.18M |
| Loss Per Share | -$27.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 741,324 |
| Total Debt | 6.56M |
| Net Cash | -5.82M |
| Net Cash Per Share | -$2.60 |
| Equity (Book Value) | 7.43M |
| Book Value Per Share | 4.59 |
| Working Capital | -17.51M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.14M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 599,989 |
| Net Borrowing | -356,379 |
| Free Cash Flow | -12.14M |
| FCF Per Share | -$5.43 |
Margins
| Measure | Value |
|---|
| Gross Margin | 95.91% |
| Operating Margin | -92.02% |
| Pretax Margin | -78.14% |
| Profit Margin | -83.05% |
| EBITDA Margin | -83.09% |
| EBIT Margin | -92.02% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -285.74% |
| Shareholder Yield | n/a |
| Earnings Yield | -2,471.33% |
| FCF Yield | -493.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.87 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |